Personalized cancer vaccine from Moderna and Merck shows breakthrough in melanoma

Moderna and Merck reported a personalized mRNA cancer vaccine used with Keytruda that reduced melanoma recurrence and spread in a trial of more than 1,000 patients, with five-year data from earlier results showing about a 50% drop in recurrence and a 59% drop in spread versus Keytruda alone; if approved, thousands of melanoma patients could benefit in the first years, and trials in other cancers (lung, bladder, kidney, pancreatic, stomach) are ongoing with results expected in the coming years.